The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck.
Antonio Jimeno
Consultant or Advisory Role - Acceleron Pharma
Marshall R. Posner
No relevant relationships to disclose
Jared Weiss
Research Funding - GlaxoSmithKline
Lori J. Wirth
No relevant relationships to disclose
Nabil F. Saba
No relevant relationships to disclose
Roger B. Cohen
No relevant relationships to disclose
Elizabeta C. Popa
No relevant relationships to disclose
Athanassios Argiris
No relevant relationships to disclose
Kenneth F. Grossmann
No relevant relationships to disclose
Ammar Sukari
No relevant relationships to disclose
Chris Korth
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Dawn Wilson
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Ty McClure
Consultant or Advisory Role - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Marat Alimzhanov
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Scott Pearsall
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Kenneth M. Attie
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Matthew L. Sherman
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Shuchi Sumant Pandya
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma